NCT04551963 2024-10-26
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
BeiGene
Phase 1 Completed
Clinical Trials
10 trialsNCT01686607 2024-10-21
MYCOS
Astellas Pharma Inc
Completed
NCT05602597 2024-03-06
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
Hutchmed
Phase 1 Completed
NCT03028103 2023-06-26
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Ipsen
Phase 1 Completed
NCT05661591 2023-04-04
Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT02222922 2020-12-17
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT04193319 2019-12-10
Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT02122770 2019-01-07
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT02093390 2016-06-06
A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects
Millennium Pharmaceuticals, Inc.
Phase 1 Completed
NCT02093728 2015-06-30
To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
AstraZeneca
Phase 1 Completed